MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Pacira Pharmaceuticals Inc-DE

Closed

SectorHealthcare

25.98 3.18

Overview

Share price change

24h

Current

Min

24.96

Max

26

Key metrics

By Trading Economics

Income

160M

16M

Sales

19M

187M

P/E

Sector Avg

11.23

57.333

EPS

0.91

Profit margin

8.566

Employees

788

EBITDA

165M

51M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+36.07% upside

Dividends

By Dow Jones

Next Earnings

6 May 2025

Market Stats

By TradingEconomics

Market Cap

-26M

1.2B

Previous open

22.8

Previous close

25.98

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Pacira Pharmaceuticals Inc-DE Chart

Past performance is not a reliable indicator of future results.

Related News

7 Apr 2025, 23:45 UTC

Hot Stocks

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

2 Jul 2024, 16:22 UTC

Major Market Movers

Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic

Peer Comparison

Price change

Pacira Pharmaceuticals Inc-DE Forecast

Price Target

By TipRanks

36.07% upside

12 Months Forecast

Average 34.29 USD  36.07%

High 65 USD

Low 21 USD

Based on 8 Wall Street analysts offering 12 month price targets forPacira Pharmaceuticals Inc-DE - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

8 ratings

3

Buy

4

Hold

1

Sell

Technical Score

By Trading Central

25.135 / 25.84Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.